Clinical trial · Interventional

Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells

Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells After Depletion of Regulatory T Cells

NCT00224354CI-TRIAL-00006954CLONTAKwithdrawnPhase 1ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

In the laboratory, we will put a special gene into cancer cells that have been taken from the subject. This gene will make the cells produce interleukin 2 (IL-2), which may help the patient's immune system kill cancer cells. Also, we will use CD40 ligand (CD40L) with the IL-2. Studies of cancers in animals and in cancer cells that are grown in laboratories have suggested adding the CD40L helps the IL-2 work better. Some of these new cells will then be given back to the subject as a vaccine shot. We believe that a part of the subject's immune system (cells called T-reg cells) might try to kill off these special cells. If the T-reg cells do that, the vaccine would not work as well or last as long. To try to avoid this, before the special cells are put back into the subject's body, we will give them an intravenous (IV) dose of IL-2 immunotoxin (called denileuk diftitox or ONTAK). ONTAK should get rid of some of the T-reg cells in the subject's body which should help the special cells work better and longer. The purpose of this study is to learn the safety and cancer-fighting effects of using IL-2 with the vaccine.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
CHRONIC LYMPHOCYTIC B-LEUKEMIA	—	UNRESOLVED	—

Interventions

Interventions (5)

Intervention	Type	Mapped drug	Match
CD40L	Biological	—	UNRESOLVED
IL-2	Biological	—	UNRESOLVED
IL-2 secreting and hCL4OL-expressing autologous B-CLL cells	Biological	—	UNRESOLVED
immunotoxin dose	Biological	—	UNRESOLVED
ONTAK	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (2)

measure
Safety of (Treg) cells using interleukin-2 immunotoxin directed to the CD25 antigen in(B-CLL) patients, then six (SC) injections of autologous leukemic cells modified to secrete (hIL-2) and to express (hCD40L).
timeFrame
15 years
measure
To obtain preliminary data on the anti-tumor effects of this treatment regimen.
timeFrame
15 years

Secondary outcomes (1)

measure
determine whether MHC-restricted or unrestricted anti-tumor immune responses are induced and sustained by the combination of Treg cell depletion and SC injections of B-CLL cells, which have been modified ex vivo to secrete hIL-2 and to express hCD40L
timeFrame
15 years

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Pre Inclusion Eligibility Criteria: Proof of B-CLL diagnosis not in Richter's transformation

Eligibility Criteria:

* Manipulated B-CLL cells available (at least 6 injections)
* B-CLL with measurable disease, not in Richter's transformation
* Life expectancy greater than or equal to 10 weeks
* ECOG 0-2 (see Section 4.3 of the full protocol for details)
* Recovered from the toxic effects of all prior chemotherapy
* Absolute neutrophil count (ANC) greater than or equal to 500/mL
* Absolute lymphocyte count (ALC) greater than or equal to 200/mL
* Hemoglobin greater than or equal to 8 g/dL
* Platelet count greater than or equal to 50,000/mL
* Total bilirubin less than or equal to 1.5mg/dL -SGOT less than or equal to 2 x Normal
* Normal PTT -Creatinine less than 3 x Normal (age-related) or Creatinine clearance \> 80mg/min/1.73m2
* Serum albumin level greater than or equal to 3 g/dl
* Must not have received treatment with other investigational agents within the last 4 weeks
* Practicing appropriate birth control during the study and for 3 months after the study is concluded.

Exclusion Criteria:

* Congestive heart failure
* Significant arrythmia or history of myocardial infarction
* Active CNS disease or a history of seizure
* Active infection / receiving antibiotics (other than prophylactic trimethoprim sulfamethoxazole
* Seropositive for HIV
* Pregnancy or lactation / will not use birth control methods
* Autoimmune disease (GvHD, immune thrombocytopenia-ITP or autoimmune hemolytic anemia-AIHA)
* Receiving immunosuppressive drugs
* Hypersensitivity to denileukin diftitox or any of its components: diphteria toxin, interleukin-2, or excipients

References

Publications (0)

Data not yet available

No reference posted for this study.